Synergism of Inflammatory Protein Markers and the Effect on Mortality in Patients with Type 2 Diabetes
Jun 2, 2020
Editor: David L. Joffe, BSPharm, CDE, FACA
Author: Deonna Andrews, PharmD Candidate 2020 of Florida Agricultural & Mechanical University College of Pharmacy and Pharmaceutical Sciences
Certain inflammatory biomarkers may help lead to improvements in the treatment of type 2 diabetes: hs-CRP and serum Amyloid P components can predict all-cause mortality.
As one of the leading causes of death worldwide, type 2 diabetes will become even more burdensome in the near future if not approached aggressively. To combat this, it is important to be able to identify patients at the highest risk for developing type 2 diabetes and use prevention strategies against it. One way to do so is to use novel biomarkers. Biomarkers improve risk stratification and may also be useful in pointing out pathogenic pathways that are still unknown that could potentially be the target of novel treatments. The objective of this study was to discover novel biomarkers capable of identifying high-risk patients who could be exposed to more aggressive preventative and treatment strategies....
Agreement to pay later is required for access to the full text of this article. You will be charged only after your use reaches $5.00 (US) of site content. The costs of producing a newsletter like Diabetes in Control have been increasing, which is why we are asking our readers to help support our ability to continue to bring you quality information about diabetes through charging a minimal price to read certain articles. Thank you for helping to support Diabetes in Control.